Suppr超能文献

局部复发性妇科癌症术中放疗根治性切除:一项机构回顾。

Radical Extirpation With Intraoperative Radiotherapy for Locally Recurrent Gynecologic Cancer: An Institutional Review.

作者信息

Delara Ritchie, Yang Jie, Suárez-Salvador Elena, Vora Sujay, Magriña Javier, Butler Kristina, Magtibay Paul

机构信息

Department of Obstetrics and Gynecology.

Department of Gynecology, Vall d'Hebron University Hospital, Barcelona, Spain.

出版信息

Mayo Clin Proc Innov Qual Outcomes. 2021 Nov 19;5(6):1081-1088. doi: 10.1016/j.mayocpiqo.2021.10.004. eCollection 2021 Dec.

Abstract

OBJECTIVE

To report survival outcomes in patients with locally recurrent gynecologic cancers managed with curative-intent radical extirpation, perioperative external beam radiotherapy, and intraoperative radiotherapy (IORT).

PATIENTS AND METHODS

We conducted a retrospective cohort analysis of 44 patients with locally recurrent gynecologic cancer treated at a single tertiary-care center (Mayo Clinic in Arizona) over a 15-year period (January 1, 2004, to July 31, 2019). This cohort included patients with uterine (n=21, 47.7%), ovarian (n=3, 6.8%), cervical (n=11, 25.0%), vaginal (n=2, 4.5%), vulvar (n=1, 2.3%), and unknown primary (n=6, 13.6%) cancer. Curative-intent radical extirpation included pelvic exenteration (n=13, 29.5%), laterally extended endopelvic resection (n=22, 50.0%), excision of para-aortic lymph node metastasis (n=8, 18.2%), and radical vaginectomy (n=1, 2.3%). Of the 44 patients in our cohort, 37 (84.1%) received IORT and 7 (15.9%) had intended to receive IORT but did not receive it.

RESULTS

The median follow-up for the 44 patients was 12 months (range, 1 to 161 months). For patients who received IORT, the median progression-free survival (PFS) and overall survival (OS) were 13 and 21 months, respectively, and the 3-year cumulative incidence of central, locoregional, and distant recurrence was 27.0% (10 of 37), 40.5% (15 of 37), and 37.8% (14 of 37), respectively. Surgical margins were classified as negative (28 of 44, 63.6%), microscopic (11 of 44, 25.0%), or macroscopic (5 of 44, 11.4%). Negative, microscopic, and macroscopic surgical margins resulted in 3-year PFS of 51.8%, 20.5%, and 0%, respectively (=.01) and 3-year OS of 62.9%, 20.0%, and 0%, respectively (=.035). Progression-free survival (=.69) and OS (=.88) were not different between patients with negative surgical margins who received (n=21) and did not receive (n=7) IORT. Ten of 37 patients (27.0%) had development of grade 3 or higher toxicities, with 1 death due to sepsis.

CONCLUSION

Complete tumor resection at the time of curative-intent radical extirpation achieved higher rates of PFS and OS regardless of IORT administration.

摘要

目的

报告采用根治性切除、围手术期外照射放疗和术中放疗(IORT)治疗的局部复发性妇科癌症患者的生存结果。

患者与方法

我们对在一家三级医疗中心(亚利桑那州梅奥诊所)接受治疗的44例局部复发性妇科癌症患者进行了回顾性队列分析,研究时间跨度为15年(2004年1月1日至2019年7月31日)。该队列包括子宫癌患者(n = 21,47.7%)、卵巢癌患者(n = 3,6.8%)、宫颈癌患者(n = 11,25.0%)、阴道癌患者(n = 2,4.5%)、外阴癌患者(n = 1,2.3%)以及原发灶不明的癌症患者(n = 6,13.6%)。根治性切除包括盆腔脏器清除术(n = 13,29.5%)、盆腔侧壁扩大切除术(n = 22,50.0%)、腹主动脉旁淋巴结转移灶切除术(n = 8,18.2%)以及根治性阴道切除术(n = 1,2.3%)。在我们的队列中,44例患者中有37例(84.1%)接受了IORT,7例(15.9%)原本打算接受IORT但未接受。

结果

44例患者的中位随访时间为12个月(范围为1至161个月)。对于接受IORT的患者,中位无进展生存期(PFS)和总生存期(OS)分别为13个月和21个月,3年中央、局部区域和远处复发的累积发生率分别为27.0%(37例中的10例)、40.5%(37例中的15例)和37.8%(37例中的14例)。手术切缘分类为阴性(44例中的28例,63.6%)、镜下阳性(44例中的11例,25.0%)或肉眼阳性(44例中的5例,11.4%)。阴性、镜下阳性和肉眼阳性手术切缘的患者3年PFS分别为51.8%、20.5%和0%(P =.01),3年OS分别为62.9%、20.0%和0%(P =.035)。接受(n = 21)和未接受(n = 7)IORT的手术切缘阴性患者的无进展生存期(P =.69)和总生存期(P =.88)无差异。37例患者中有10例(27.0%)出现3级或更高等级的毒性反应,1例因败血症死亡。

结论

无论是否进行IORT,根治性切除时完全切除肿瘤可实现更高的PFS和OS率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb89/8606340/197bdb3cfc70/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验